Abstract
A fixed-dose combination tablet comprising the hepatitis C virus (HCV) NS5A inhibitor elbasvir and the HCV NS3/4A protease inhibitor grazoprevir (elba......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
